Selected article for: "MERS cov and spike protein"

Author: Roman Woelfel; Victor Max Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Mueller; Daniela Niemeyer; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Bruenink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner
Title: Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster
  • Document date: 2020_3_8
  • ID: gunn55f9_49
    Snippet: We performed recombinant immunofluorescence assays to determine the specific reactivity against recombinant spike proteins in VeroB4 cells, as described 11,12 . This assay used cloned CoV spike protein from HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, and SARS-CoV-2. The screening dilution was 1:10. Plaque reduction neutralization tests were done essentially as previously described for MERS-CoV 12 . Serum dilutions causing plaque reductions of 90%.....
    Document: We performed recombinant immunofluorescence assays to determine the specific reactivity against recombinant spike proteins in VeroB4 cells, as described 11,12 . This assay used cloned CoV spike protein from HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, and SARS-CoV-2. The screening dilution was 1:10. Plaque reduction neutralization tests were done essentially as previously described for MERS-CoV 12 . Serum dilutions causing plaque reductions of 90% (PRNT90) and 50% (PRNT50) were recorded as titers. Additional technical details are provided in Section 2b and 2c in the Supplementary Appendix.

    Search related documents:
    Co phrase search for related documents